Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xomage
- Development stage
- Unknown
- Lead developer
- Zishel Bio
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intradermal, Topical
01
Overview
Xomage is an exosome-based therapy developed by Zishel Bio Inc. It contains adipose-derived mesenchymal stem cell exosomes (ADMSCs-EXOs) that offer a promising approach for skin and hair treatments. Each vial contains 10 billion exosome particles combined with growth factors, peptides, and plant-derived extracellular vesicles. The exosomes have the ability to circulate in the body for extended periods with higher penetration ability and promote strengthening of fibroblast activity. Clinical studies have shown effectiveness when combined with needle radiofrequency therapy for treating acne.
- Other names
- ZISHEL XOMAGE
Beyond the preview
Go deeper on Xomage.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xomage.